Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autoimmune disorder characterized by the association of primary biliary cirrhosis (PBC) with limited cutaneous systemic sclerosis (lcSSc).
Features include always present findings: Cholestasis, Anti-centromere antibody positivity, Antinuclear antibody positivity, and Palmar telangiectasia and others. 26 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 7 | Cholestasis, Enlarged liver (hepatomegaly), Biliary cirrhosis |
LBR encodes lamin B receptor (615 aa). Catalyzes the reduction of the C14-unsaturated bond of lanosterol, as part of the metabolic pathway leading to cholesterol biosynthesis. Highest expression in Colon Sigmoid (89.3 TPM) and Cells EBV-transformed lymphocytes (88.9 TPM).
Reynolds syndrome is associated with mutations in the LBR gene on chromosome 1.
The LBR protein participates in 4,4-dimethylcholesta-8(9),14,24-trien-3beta-ol is reduced to 4,4-dimethylcholesta-8(9),24-dien-3beta-ol [LBR], 4,4-dimethylcholesta-8(9),14,24-trien-3beta-ol is reduced to 4,4-dimethylcholesta-8(9),24-dien-3beta-ol [TM7SF2], and RHOC activates endoplasmic reticulum effectors pathways.
LBR is classified as a druggable target with score 0.0.
Genetic testing for LBR is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 11 always present features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Reynolds syndrome.
9 publications have been identified in PubMed for Reynolds syndrome. Research spans Review / Meta-Analysis (44%), Case Report / Case Series (33%), and Epidemiology / Natural History (22%).
Zhou AE (2025). [PMID: 41187239](https://pubmed.ncbi.nlm.nih.gov/41187239/). *Journal of drugs in dermatology : JDD*. [Case Report / Case Series]
Ando Y (2025). [PMID: 40764937](https://pubmed.ncbi.nlm.nih.gov/40764937/). *Journal of medical case reports*. [Case Report / Case Series]
Thakkar HH (2025). [PMID: 40351968](https://pubmed.ncbi.nlm.nih.gov/40351968/). *Cureus*. [Review / Meta-Analysis]
Luo Y (2025). [PMID: 39676709](https://pubmed.ncbi.nlm.nih.gov/39676709/). *Arthritis & rheumatology (Hoboken, N.J.)*. [Review / Meta-Analysis]
Memon A (2025). [PMID: 40916985](https://pubmed.ncbi.nlm.nih.gov/40916985/). *Current opinion in rheumatology*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 2:56 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Reynolds syndrome
Lab test results
6 |
Anti-centromere antibody positivity, Elevated circulating alkaline phosphatase concentration, Antinuclear antibody positivity |
Skin | 4 | Palmar telangiectasia, Lip telangiectasia, Erythema nodosum |
Blood and immune system | 1 | Enlarged spleen (splenomegaly) |
Head and neck | 1 | Lip telangiectasia |
Bones and joints | 1 | Arthralgia |
Ma G (2024). [PMID: 38773317](https://pubmed.ncbi.nlm.nih.gov/38773317/). *Scientific reports*. [Epidemiology / Natural History]
Zhang HP (2024). [PMID: 39210292](https://pubmed.ncbi.nlm.nih.gov/39210292/). *BMC gastroenterology*. [Epidemiology / Natural History]
Abe K (2024). [PMID: 38898064](https://pubmed.ncbi.nlm.nih.gov/38898064/). *Scientific reports*. [Case Report / Case Series]